EPIQ Series Diagnostic Ultrasound System

The Philips EPIQ Series Diagnostic Ultrasound System introduces 3D Auto TV and 3D Auto CFQ software to semi-automate quantification of tricuspid valve anatomy and mitral regurgitation volume, enhancing cardiac adult diagnostic capabilities without hardware changes. These new applications were validated through non-clinical performance studies, demonstrating high agreement with reference methods like CMR and 2D PISA, confirming their safe and effective performance for clinical use.

Philips Ultrasound LLC has enhanced its EPIQ Series Diagnostic Ultrasound System with new software capabilities: 3D Auto TV for semi-automated tricuspid valve quantification and 3D Auto CFQ for semi-automated mitral regurgitation volume and peak flow rate. These additions expand the system's existing diagnostic imaging and fluid flow analysis capabilities, specifically for cardiac adult indications, without requiring any hardware modifications. The device maintains its broad intended use across various diagnostic applications in clinical, hospital, and point-of-care environments. Non-clinical verification and performance validation studies were conducted to ensure the continued safety and effectiveness of these updates. The 3D Auto TV software showed high agreement with a reference application for tricuspid valve annulus measurements, while the 3D Auto CFQ software's performance for mitral regurgitation quantification met all predefined acceptance criteria when evaluated against cardiac magnetic resonance imaging (CMR) and the 2D PISA method. These tests confirmed that the updated device performs as intended, is comparable to previously available versions, and poses no new safety or effectiveness concerns.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific clinical benefits or improved diagnostic accuracy do these new software features offer over previous methods or devices?; How does the semi-automated quantification compare to fully manual or other established automated methods in terms of accuracy, reproducibility, and time efficiency?; Are there specific patient populations or cardiac conditions where these new software capabilities provide unique diagnostic insights not achievable with other imaging modalities?; What is the learning curve for clinicians to effectively utilize and interpret the results from the 3D Auto TV and 3D Auto CFQ software?; Have studies been conducted to assess the long-term impact of improved diagnosis using these new features on patient management and outcomes?